Tina Fanoe - Novozymes Executive Vice President Agriculture & Bioenergy
| NVZMY Stock | USD 58.24 0.78 1.32% |
President
Ms. Tina Sejersgaard Fanoe was Executive Vice President, Agriculture Bioenergy at Novozymes AS since February 8, 2016. She is also Board Member of DLF AS. Previously, she was Vice President of Sales at the Company. She holds a MS in Chemical Engineering from the Technical University of Denmark, as well as a Bachelor of Arts degree in philosophy and education from Copenhagen University, Denmark. She started her career with the company in 1993 and has held various positions within RD, Marketing, Business Development and Sales. since 2016.
| Age | 54 |
| Tenure | 8 years |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Heidi Petz | Sherwin Williams Co | 49 | |
| Sean Major | Air Products and | 60 | |
| Francesco Maione | Air Products and | N/A | |
| Francisco Fortanet | International Flavors Fragrance | 52 | |
| Karen Narwold | Albemarle Corp | 61 | |
| Maurizio Volpi | Givaudan SA | 54 | |
| Wolfgang Brand | Air Products and | 47 | |
| Vic Verma | International Flavors Fragrance | 55 | |
| Brian Williams | PPG Industries | N/A | |
| Anne Foulkes | PPG Industries | 61 | |
| Richard Gilmore | Sherwin Williams Co | 55 | |
| Aaron Erter | Sherwin Williams Co | 45 | |
| Colin Davie | Sherwin Williams Co | 55 | |
| JeanMarc Royere | Air Liquide SA | 58 | |
| Michael Graff | Air Liquide SA | 68 | |
| Bryan Young | Sherwin Williams Co | 48 | |
| David Sewell | Sherwin Williams Co | 51 | |
| Thomas Gilligan | Sherwin Williams Co | 63 | |
| Kristin Esq | Albemarle Corp | 56 | |
| Pedro Salvat | PPG Industries | N/A | |
| Vincent Morales | PPG Industries | 58 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pedro Fernandes, Head America | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Graziela Malucelli, Supply Operations | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Morten Rasmussen, Sustainability People | ||
| MSc MSc, Ex CFO |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.